摘要
目的探讨多巴胺联合呋塞米治疗肝腹水的临床疗效与安全性。方法方便选取2013年1月—2017年11月该院收治的98例肝腹水患者为研究对象,随机将入选病例分为实验组(多巴胺联合呋塞米,49例)和对照组(呋塞米,49例),对比观察两组疗效,统计并发症。结果实验组治疗总有效率(91.84%)高于对照组(75.51%),差异有统计学意义(χ2=6.37,P<0.05);实验组不良反应发生率(10.20%)与对照组(8.16%)比较差异无统计学意义(χ2=1.41,P>0.05)。结论多巴胺联合呋塞米腹腔注射治疗肝腹水效果优于单纯呋塞米治疗,而且不会增加患者不良反应,用药安全有效,值得临床推广。
Objective This paper tries to investigate the clinical efficacy and safety of dopamine and furosemide in treatment of liver ascites.Methods 98 cases of liver ascites patients from January 2013 to November 2017 in this hospital were convenient selected as the research object,and were divided into experimental group(dopamine and furosemide,49 cases)and control group(furosemide,49 cases),the effect of two groups was observed and the complications were statistically analyzed.Results The total effective rate of the experimental group(91.84%)was higher than that of the control group(75.51%),the difference was statistically significant(χ2=6.37,P<0.05);the incidence of adverse reactions in the experimental group(10.20%)was not significantly different from that in the control group(8.16%)(χ2=1.41,P>0.05).Conclusion The curative effect of dopamine and furosemide treated with intraperitoneal perfusion of liver ascites is better than furosemide treatment,and will not increase the adverse reactions of patients,which is safe and effective,worthy of promotion.
作者
吕锋
LYU Feng(Infection Department,Xinghua People’s Hospital,Xinghua,Jiangsu Province,225700 China)
出处
《中外医疗》
2018年第7期106-107,111,共3页
China & Foreign Medical Treatment
关键词
肝腹水
多巴胺
呋塞米
联合治疗
效果
安全性
Liver ascites
Dopamine
Furosemide
Combined therapy
Efficacy
Safety
